This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
World Health Organization. Global hepatitis report 2024: Action for access in low-and middle-income countries. April 2024. Available from https://www.who.int/publications/i/item/9789240091672 (accessed May 2025).World Health OrganizationGlobal hepatitis report 2024: Action for access in low-and middle-income countriesApril2024Available from https://www.who.int/publications/i/item/9789240091672 (accessed May 2025).Search in Google Scholar
World Health Organization. Hepatitis B. Available from https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b (accessed May 2025).World Health OrganizationHepatitis BAvailable from https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b (accessed May 2025).Search in Google Scholar
Zampino R, Boemio A, Sagnelli C, et al. 2015. Hepatitis B virus burden in developing countries. World J Gastroenterol 2015; 21(42):11941. doi: 10.3748/wjg.v21.i42.11941.ZampinoRBoemioASagnelliC2015.Hepatitis B virus burden in developing countriesWorld J Gastroenterol201521421194110.3748/wjg.v21.i42.11941Open DOISearch in Google Scholar
Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386(10003):1546–55. doi: 10.1016/S0140-6736(15)61412-X.SchweitzerAHornJMikolajczykRTEstimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013Lancet20153861000315465510.1016/S0140-6736(15)61412-XOpen DOISearch in Google Scholar
Kiire C. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: A view from tropical and subtropical Africa. Gut 1996; 38(Suppl 2): S5–12. doi: 10.1136/gut.38.suppl_2.s5.KiireCThe epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: A view from tropical and subtropical AfricaGut199638Suppl 2S51210.1136/gut.38.suppl_2.s5Open DOISearch in Google Scholar
Kew MC. Hepatitis B virus infection: The burden of disease in South Africa. Southern African Journal of Epidemiology and Infection 2008; 23(1): 4–8. doi: 10.1080/10158782.2008.11441293.KewMCHepatitis B virus infection: The burden of disease in South AfricaSouthern African Journal of Epidemiology and Infection20082314810.1080/10158782.2008.11441293Open DOISearch in Google Scholar
Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ 2020; 370: m2200. doi: https://doi.org/10.1136/bmj.m2200ShiYZhengMHepatitis B virus persistence and reactivationBMJ2020370m2200doi: https://doi.org/10.1136/bmj.m2200Search in Google Scholar
Yip TCF, Wong GLH. Current knowledge of occult hepatitis B infection and clinical implications. Semin Liver Dis 2019; 39(2): 249–60. doi: 10.1055/s-0039-1678728.YipTCFWongGLHCurrent knowledge of occult hepatitis B infection and clinical implicationsSemin Liver Dis20193922496010.1055/s-0039-1678728Open DOISearch in Google Scholar
Raimondo G, Locarnini S, Pollicino T, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 2019; 71(2):397–408. doi: 10.1016/j.jhep.2019.03.034RaimondoGLocarniniSPollicinoTUpdate of the statements on biology and clinical impact of occult hepatitis B virus infectionJ Hepatol201971239740810.1016/j.jhep.2019.03.034Open DOISearch in Google Scholar
Ocana S, Casas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus infection. World J Gastroenterol 2011; 17(12):1553. doi: 10.3748/wjg.v17.i12.1553.OcanaSCasasMLBuhigasILledoJLDiagnostic strategy for occult hepatitis B virus infectionWorld J Gastroenterol20111712155310.3748/wjg.v17.i12.1553Open DOISearch in Google Scholar
Kramvis A. Molecular characteristics and clinical relevance of African genotypes and subgenotypes of hepatitis B virus. S Afr Med J 2018; 108(8):17–21. doi: 10.7196/samj.2018.v108i8.13495.KramvisAMolecular characteristics and clinical relevance of African genotypes and subgenotypes of hepatitis B virusS Afr Med J20181088172110.7196/samj.2018.v108i8.13495Open DOISearch in Google Scholar
Hwang EW, Cheung R. Global epidemiology of hepatitis B virus (HBV) infection. North American Journal of Medicine and Science 2011; 4(1):7–13. Available from https://najms.com/index.php/najms/article/view/499 (accessed May 2025).HwangEWCheungRGlobal epidemiology of hepatitis B virus (HBV) infectionNorth American Journal of Medicine and Science201141713Available from https://najms.com/index.php/najms/article/view/499 (accessed May 2025).Search in Google Scholar
Im YR, Jagdish R, Leith D, et al. Prevalence of occult hepatitis B virus infection in adults: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022; 7(10): 932–42. doi: 10.1016/S2468-1253(22)00201-1.ImYRJagdishRLeithDPrevalence of occult hepatitis B virus infection in adults: A systematic review and meta-analysisLancet Gastroenterol Hepatol20227109324210.1016/S2468-1253(22)00201-1Open DOISearch in Google Scholar
Weusten J, Van Drimmelen H, Vermeulen M, Lelie N. A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios. Transfusion 2017; 57(3pt2): 841–9. doi: 10.1111/trf.14050.WeustenJVan DrimmelenHVermeulenMLelieNA mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenariosTransfusion2017573pt2841910.1111/trf.14050Open DOISearch in Google Scholar
Candotti D, Boizeau L, Laperche S. Occult hepatitis B infection and transfusion-transmission risk. Transfus Clin Biol 2017; 24(3): 189–95. doi: 10.1016/j.tracli.2017.06.014.CandottiDBoizeauLLapercheSOccult hepatitis B infection and transfusion-transmission riskTransfus Clin Biol20172431899510.1016/j.tracli.2017.06.014Open DOISearch in Google Scholar
Makris M, Preston F, Triger D, et al. Hepatitis c antibody and chronic liver disease in haemophilia. Lancet 1990; 335(8698): 1117–9. doi: 10.1016/0140-6736(90)91124-S.MakrisMPrestonFTrigerDHepatitis c antibody and chronic liver disease in haemophiliaLancet199033586981117910.1016/0140-6736(90)91124-SOpen DOISearch in Google Scholar
Merritt EC. Infected blood scandal: Background, impacts, interim compensation and inquiry outcomes. [cited 2024; 2024/08/05]. Available from: https://lordslibrary.parliament.uk/infected-blood-scandal-background-impacts-interim-compensation-and-inquiry-outcomes.MerrittECInfected blood scandal: Background, impacts, interim compensation and inquiry outcomes. [cited 2024; 2024/08/05]Available from: https://lordslibrary.parliament.uk/infected-blood-scandal-background-impacts-interim-compensation-and-inquiry-outcomes.Search in Google Scholar
Teitel JM. Viral safety of haemophilia treatment products. Ann Med 2000; 32(7):485–92. doi: 10.3109/07853890009002024.TeitelJMViral safety of haemophilia treatment productsAnn Med20003274859210.3109/07853890009002024Open DOISearch in Google Scholar
Allain JO, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 2009; 49(6): 1868–76. doi: 10.1002/hep.22879.AllainJOBelkhiriDVermeulenMCharacterization of occult hepatitis B virus strains in South African blood donorsHepatology200949618687610.1002/hep.22879Open DOISearch in Google Scholar
Bell TG, Makondo E, Martinson NA, Kramvis A. Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: Occult or overt–that is the question. PLoS One 2012; 7(10): e45750. doi: 10.1371/journal.pone.0045750.BellTGMakondoEMartinsonNAKramvisAHepatitis B virus infection in human immunodeficiency virus infected southern African adults: Occult or overt–that is the questionPLoS One2012710e4575010.1371/journal.pone.0045750Open DOISearch in Google Scholar
Msomi N|, Ndlovu K, Gianhari J, et al. High rate of occult hepatitis B virus infection in hemodialysis units of KwaZulu-Natal, South Africa. J Med Virol 2019; 91(10): 1797–803. doi: 10.1002/jmv.25510.MsomiNNdlovuKGianhariJHigh rate of occult hepatitis B virus infection in hemodialysis units of KwaZulu-Natal, South AfricaJ Med Virol20199110179780310.1002/jmv.25510Open DOISearch in Google Scholar
Javanmard D, Namaei MH, Farahmand M, et al. Molecular and serological characterization of occult hepatitis B virus infection among patients with hemophilia. J Med Virol 2019; 91(8): 1519–27. doi: 10.1002/jmv.25470.JavanmardDNamaeiMHFarahmandMMolecular and serological characterization of occult hepatitis B virus infection among patients with hemophiliaJ Med Virol201991815192710.1002/jmv.25470Open DOISearch in Google Scholar
Toyoda H, Hayashi K, Murakami Y, et al. Prevalence and clinical implications of occult hepatitis b viral infection in hemophilia patients in Japan. J Med Virol 2004; 73(2): 195–9. doi: 10.1002/jmv.20075.ToyodaHHayashiKMurakamiYPrevalence and clinical implications of occult hepatitis b viral infection in hemophilia patients in JapanJ Med Virol2004732195910.1002/jmv.20075Open DOISearch in Google Scholar
Varaklioti A, Kouramba A, Ioannidou P, Katsarou O. Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders. Infect Genet Evol 2017; 54: 397–401. doi: 10.1016/j.meegid.2017.07.012.VarakliotiAKourambaAIoannidouPKatsarouOOccult hepatitis B virus infection in Greek patients with congenital bleeding disordersInfect Genet Evol20175439740110.1016/j.meegid.2017.07.012Open DOISearch in Google Scholar
Windyga J, Brojer E, Gronowska A, et al. Preliminary results of HBV DNA testing of Polish haemophilia patients–lack of occult HBV infection. Haemophilia 2006; 12(4): 380–3. doi: 10.1111/j.1365-2516.2006.01293.x.WindygaJBrojerEGronowskaAPreliminary results of HBV DNA testing of Polish haemophilia patients–lack of occult HBV infectionHaemophilia2006124380310.1111/j.1365-2516.2006.01293.xOpen DOISearch in Google Scholar
Spearman CW, Afihene M, Ally R, et al. Hepatitis B in sub-Saharan Africa: Strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol 2017; 2(12): 900–9. doi: 10.1016/S2468-1253(17)30295-9.SpearmanCWAfiheneMAllyRHepatitis B in sub-Saharan Africa: Strategies to achieve the 2030 elimination targetsLancet Gastroenterol Hepatol2017212900910.1016/S2468-1253(17)30295-9Open DOISearch in Google Scholar
Vermeulen M, Swanevelder R, Van Zyl G, Lelie N, Murphy EL. An assessment of hepatitis B virus prevalence in South African young blood donors born after the implementation of the infant hepatitis B virus immunization program: Implications for transfusion safety. Transfusion 2021; 61(9): 2688–700. doi: 10.1111/trf.16559.VermeulenMSwanevelderRVan ZylGLelieNMurphyELAn assessment of hepatitis B virus prevalence in South African young blood donors born after the implementation of the infant hepatitis B virus immunization program: Implications for transfusion safetyTransfusion2021619268870010.1111/trf.16559Open DOISearch in Google Scholar
European Medicines Agency. Guideline on plasma-derived medicinal products. 21 July 2011. EMA/CHMP/BWP/706271/2010. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf (accessed June 2025).European Medicines AgencyGuideline on plasma-derived medicinal products21July2011EMA/CHMP/BWP/706271/2010Available from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf (accessed June 2025).Search in Google Scholar
Samal J, Kandpal M. Vivekandandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25(1): 142–63. doi: 10.1128/CMR.00018-11.SamalJKandpalMVivekandandan P. Molecular mechanisms underlying occult hepatitis B virus infectionClin Microbiol Rev20122511426310.1128/CMR.00018-11Open DOISearch in Google Scholar